ABBV 011
Alternative Names: ABBV-011; SC-011Latest Information Update: 28 Dec 2024
At a glance
- Originator AbbVie
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA damage stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Small cell lung cancer
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Monotherapy, Second-line therapy or greater) in USA (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Combination therapy, Second-line therapy or greater) in Japan (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Monotherapy, Second-line therapy or greater) in Japan (IV)